Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications.
Mattia GalliFrancesco FranchiFabiana RolliniLuis Ortega-PazDomenico D'AmarioRaffaele De CaterinaRoxana MehranC Michael GibsonDominick J AngiolilloPublished in: Expert review of clinical pharmacology (2022)
The implementation of a DPI by adding the so-called "vascular dose of rivaroxaban" (i.e., 2.5 mg bis in die), on top of antiplatelet therapy has consistently been associated with reduced levels of thrombin generation in PD studies and with reduced ischemic event rates at the cost of increased bleeding compared to antiplatelet therapy alone. Further research is warranted to best define patients in whom a DPI regimen has the best safety and efficacy profile.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- end stage renal disease
- atrial fibrillation
- ejection fraction
- newly diagnosed
- primary care
- chronic kidney disease
- healthcare
- venous thromboembolism
- coronary artery disease
- peritoneal dialysis
- prognostic factors
- ionic liquid
- quality improvement
- oxidative stress
- blood brain barrier